1. “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice” Int J Pharma. 2026, 694:126752. (https://doi.org/10.1016/j.ijpharm.2026.126752) (Impact Factor: 5.2, 3rd most cited journal in Pharmacy & Pharmacology out of 366 journals)
2. “TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity” Haematologica. 2025, Nov 6. (https://doi.org/10.3324/haematol.2025.288692) (Impact Factor: 7.9, 8th-10th out of ~75-120+ journals in the Hematology category)
3. “2FA-platform generates dual fatty acid-conjugated GLP‑1 receptor agonist TE-8105 with enhanced diabetes, obesity, and NASH efficacy compared to semaglutide” J. Med. Chem. 2025, 68, 6178-6192. (https://doi.org/10.1021/acs.jmedchem.4c02153) (Impact Factor: 6.8, 3rd out of 72 journals in the Medicinal Chemistry category)
4. “An antibody-drug conjugate for multiple myeloma prepared by multi-arm linkers” Adv. Sci. 2024, 2307852. (https://doi.org/10.1002/advs.202307852) (Impact Factor: 14.1, Top 7-8% in Nanoscience & Nanotechnology)
5. “Site-specific conjugation of 6 DOTA chelators to a CA19-9-targeting scFv-Fc antibody for imaging and therapy” J. Med. Chem. 2023, 66, 10604-10616. (https://doi.org/10.1021/acs.jmedchem.3c00753) (Impact Factor: 6.8, 3rd out of 72 journals in the Medicinal Chemistry category)